Cellectis (ALCLS) investor relations material

Executive summary

• Reported Q1 2026 financial results and provided business updates on clinical and preclinical programs.

• Interim pivotal data for cema-cel (licensed product) showed strong MRD negativity and safety profile.

• Cash position of $188 million as of March 31, 2026, expected to fund operations into Q4 2027.

Financial highlights

• Revenues and other income were $7.5 million for Q1 2026, down from $12.0 million in Q1 2025, mainly due to lower revenues from the AstraZeneca collaboration.

• R&D expenses increased to $27.2 million from $21.9 million year-over-year, driven by higher personnel and external costs.

• SG&A expenses rose to $5.6 million from $4.7 million, mainly due to increased stock-based compensation and other expenses.

• Net financial gain of $7.4 million in Q1 2026, compared to a $3.9 million loss in Q1 2025, due to gains on warrant fair value and FX movements.

• Net loss attributable to shareholders was $17.8 million ($0.18/share), slightly improved from $18.1 million ($0.18/share) in Q1 2025.

• Adjusted net loss was $16.1 million ($0.16/share), compared to $17.2 million ($0.17/share) in Q1 2025.

Outlook and guidance

• Interim analysis for pivotal Phase 2 BALLI-01 trial expected in Q4 2026; BLA submission anticipated in 2028.

• Full Phase 1 dataset for eti-cel in NHL expected in Q4 2026.

• Cash runway projected into Q4 2027, supporting ongoing clinical development and manufacturing.